The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cutaneous Leishmaniasis Drugs Market Research Report 2025
Synopsis
Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
The global Cutaneous Leishmaniasis Drugs market was valued at US$ 43 million in 2023 and is anticipated to reach US$ 57 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
This report aims to provide a comprehensive presentation of the global market for Cutaneous Leishmaniasis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cutaneous Leishmaniasis Drugs.
Report Scope
The Cutaneous Leishmaniasis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cutaneous Leishmaniasis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cutaneous Leishmaniasis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cutaneous Leishmaniasis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cutaneous Leishmaniasis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
The global Cutaneous Leishmaniasis Drugs market was valued at US$ 43 million in 2023 and is anticipated to reach US$ 57 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
This report aims to provide a comprehensive presentation of the global market for Cutaneous Leishmaniasis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cutaneous Leishmaniasis Drugs.
Report Scope
The Cutaneous Leishmaniasis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cutaneous Leishmaniasis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cutaneous Leishmaniasis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cutaneous Leishmaniasis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cutaneous Leishmaniasis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Cutaneous Leishmaniasis Drugs Market Overview
1.1 Product Overview and Scope of Cutaneous Leishmaniasis Drugs
1.2 Cutaneous Leishmaniasis Drugs Segment by Type
1.2.1 Global Cutaneous Leishmaniasis Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Pentavalent Antimonials
1.2.3 Antifungal Drugs
1.2.4 Anti-Leishmanial/Antimicrobial Drugs
1.3 Cutaneous Leishmaniasis Drugs Segment by Application
1.3.1 Global Cutaneous Leishmaniasis Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Cutaneous Leishmaniasis Drugs Market Size Estimates and Forecasts
1.4.1 Global Cutaneous Leishmaniasis Drugs Revenue 2019-2030
1.4.2 Global Cutaneous Leishmaniasis Drugs Sales 2019-2030
1.4.3 Global Cutaneous Leishmaniasis Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Cutaneous Leishmaniasis Drugs Market Competition by Manufacturers
2.1 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Cutaneous Leishmaniasis Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Cutaneous Leishmaniasis Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cutaneous Leishmaniasis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cutaneous Leishmaniasis Drugs, Product Type & Application
2.7 Cutaneous Leishmaniasis Drugs Market Competitive Situation and Trends
2.7.1 Cutaneous Leishmaniasis Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cutaneous Leishmaniasis Drugs Players Market Share by Revenue
2.7.3 Global Cutaneous Leishmaniasis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cutaneous Leishmaniasis Drugs Retrospective Market Scenario by Region
3.1 Global Cutaneous Leishmaniasis Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Cutaneous Leishmaniasis Drugs Global Cutaneous Leishmaniasis Drugs Sales by Region: 2019-2030
3.2.1 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2019-2024
3.2.2 Global Cutaneous Leishmaniasis Drugs Sales by Region: 2025-2030
3.3 Global Cutaneous Leishmaniasis Drugs Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2019-2030
3.3.1 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2019-2024
3.3.2 Global Cutaneous Leishmaniasis Drugs Revenue by Region: 2025-2030
3.4 North America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
3.4.1 North America Cutaneous Leishmaniasis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Cutaneous Leishmaniasis Drugs Sales by Country (2019-2030)
3.4.3 North America Cutaneous Leishmaniasis Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
3.5.1 Europe Cutaneous Leishmaniasis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Cutaneous Leishmaniasis Drugs Sales by Country (2019-2030)
3.5.3 Europe Cutaneous Leishmaniasis Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Cutaneous Leishmaniasis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Cutaneous Leishmaniasis Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
3.7.1 Latin America Cutaneous Leishmaniasis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Cutaneous Leishmaniasis Drugs Sales by Country (2019-2030)
3.7.3 Latin America Cutaneous Leishmaniasis Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2019-2030)
4.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2019-2024)
4.1.2 Global Cutaneous Leishmaniasis Drugs Sales by Type (2025-2030)
4.1.3 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2019-2030)
4.2 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2019-2030)
4.2.1 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2019-2024)
4.2.2 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2025-2030)
4.2.3 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Cutaneous Leishmaniasis Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2019-2030)
5.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2019-2024)
5.1.2 Global Cutaneous Leishmaniasis Drugs Sales by Application (2025-2030)
5.1.3 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2019-2030)
5.2 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2019-2030)
5.2.1 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2019-2024)
5.2.2 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2025-2030)
5.2.3 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Cutaneous Leishmaniasis Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Cutaneous Leishmaniasis Drugs Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Cutaneous Leishmaniasis Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Cutaneous Leishmaniasis Drugs Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Gilead Sciences
6.4.1 Gilead Sciences Corporation Information
6.4.2 Gilead Sciences Description and Business Overview
6.4.3 Gilead Sciences Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Gilead Sciences Cutaneous Leishmaniasis Drugs Product Portfolio
6.4.5 Gilead Sciences Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Albert David
6.6.1 Albert David Corporation Information
6.6.2 Albert David Description and Business Overview
6.6.3 Albert David Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Albert David Cutaneous Leishmaniasis Drugs Product Portfolio
6.6.5 Albert David Recent Developments/Updates
6.7 Profounda
6.6.1 Profounda Corporation Information
6.6.2 Profounda Description and Business Overview
6.6.3 Profounda Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Profounda Cutaneous Leishmaniasis Drugs Product Portfolio
6.7.5 Profounda Recent Developments/Updates
6.8 Knight Therapeutics
6.8.1 Knight Therapeutics Corporation Information
6.8.2 Knight Therapeutics Description and Business Overview
6.8.3 Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Knight Therapeutics Cutaneous Leishmaniasis Drugs Product Portfolio
6.8.5 Knight Therapeutics Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer Cutaneous Leishmaniasis Drugs Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Xinhua Pharma
6.10.1 Xinhua Pharma Corporation Information
6.10.2 Xinhua Pharma Description and Business Overview
6.10.3 Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Xinhua Pharma Cutaneous Leishmaniasis Drugs Product Portfolio
6.10.5 Xinhua Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cutaneous Leishmaniasis Drugs Industry Chain Analysis
7.2 Cutaneous Leishmaniasis Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cutaneous Leishmaniasis Drugs Production Mode & Process
7.4 Cutaneous Leishmaniasis Drugs Sales and Marketing
7.4.1 Cutaneous Leishmaniasis Drugs Sales Channels
7.4.2 Cutaneous Leishmaniasis Drugs Distributors
7.5 Cutaneous Leishmaniasis Drugs Customers
8 Cutaneous Leishmaniasis Drugs Market Dynamics
8.1 Cutaneous Leishmaniasis Drugs Industry Trends
8.2 Cutaneous Leishmaniasis Drugs Market Drivers
8.3 Cutaneous Leishmaniasis Drugs Market Challenges
8.4 Cutaneous Leishmaniasis Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
